Skip to main content
Top
Published in: memo - Magazine of European Medical Oncology 1/2020

01-03-2020 | Care | short review

Palliative sedation for delirium management at the end of life

Author: Sophie Roider-Schur

Published in: memo - Magazine of European Medical Oncology | Issue 1/2020

Login to get access

Summary

Delirium is a frequent neurocognitive complication in cancer patients, particularly in advanced stage and terminal disease. It is associated with increased morbidity and mortality and is a critical source of stress for patients and caregivers. For healthcare staff, delirium poses significant challenges in diagnosis and treatment as well as assessment of other symptoms due to its fluctuating nature, communication impediments, and possible agitation in hyperactive subtypes. Pathophysiological mechanisms underlying delirium are complex, but the approach to adequate symptom management consists of nonpharmacological strategies as well as the use of antipsychotic agents. However, when nonreversible and refractory delirium occurs, palliative sedation is an invaluable treatment option and may be offered after careful consideration. This short review attempts to cover important aspects of clinical features of delirium, diagnostic and treatment strategies as well as the role of palliative sedation in refractory situations in delirious cancer patients at the end of life.
Literature
1.
go back to reference Cherny NI, Group EGW. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143–iii52.CrossRef Cherny NI, Group EGW. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143–iii52.CrossRef
2.
go back to reference Cherny NI, Radbruch L, Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581–93.CrossRef Cherny NI, Radbruch L, Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581–93.CrossRef
3.
go back to reference Cherny NI. Sedation for the care of patients with advanced cancer. Nat Clin Pract Oncol. 2006;3(9):492–500.CrossRef Cherny NI. Sedation for the care of patients with advanced cancer. Nat Clin Pract Oncol. 2006;3(9):492–500.CrossRef
4.
go back to reference Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30(12):1378–83.CrossRef Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30(12):1378–83.CrossRef
5.
go back to reference Fainsinger RL, De Moissac D, Mancini I, Oneschuk D. Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care. 2000;16(2):5–10.CrossRef Fainsinger RL, De Moissac D, Mancini I, Oneschuk D. Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care. 2000;16(2):5–10.CrossRef
6.
go back to reference Schur S, Weixler D, Gabl C, et al. Sedation at the end of life—a nation-wide study in palliative care units in Austria. BMC Palliat Care. 2016;15:50.CrossRef Schur S, Weixler D, Gabl C, et al. Sedation at the end of life—a nation-wide study in palliative care units in Austria. BMC Palliat Care. 2016;15:50.CrossRef
7.
go back to reference Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. Nat Rev Clin Oncol. 2015;12(2):77–92.CrossRef Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. Nat Rev Clin Oncol. 2015;12(2):77–92.CrossRef
8.
go back to reference Bush SH, Lawlor PG, Ryan K, et al. Delirium in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv143–iv65.CrossRef Bush SH, Lawlor PG, Ryan K, et al. Delirium in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv143–iv65.CrossRef
9.
go back to reference Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786–94.CrossRef Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786–94.CrossRef
10.
go back to reference de la Cruz M, Ransing V, Yennu S, et al. The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit. Oncologist. 2015;20(12):1425–31.CrossRef de la Cruz M, Ransing V, Yennu S, et al. The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit. Oncologist. 2015;20(12):1425–31.CrossRef
11.
go back to reference Mercadante S, Adile C, Ferrera P, Cortegiani A, Casuccio A. Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit. Curr Med Res Opin. 2017;33(7):1303–8.CrossRef Mercadante S, Adile C, Ferrera P, Cortegiani A, Casuccio A. Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit. Curr Med Res Opin. 2017;33(7):1303–8.CrossRef
12.
go back to reference Kim SY, Kim SW, Kim JM, et al. Differential associations between delirium and mortality according to delirium subtype and age: a prospective cohort study. Psychosom Med. 2015;77(8):903–10.CrossRef Kim SY, Kim SW, Kim JM, et al. Differential associations between delirium and mortality according to delirium subtype and age: a prospective cohort study. Psychosom Med. 2015;77(8):903–10.CrossRef
13.
go back to reference Lawlor PG, Davis DHJ, Ansari M, et al. An analytical framework for delirium research in palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge user perspectives. J Pain Symptom Manage. 2014;48(2):159–75.CrossRef Lawlor PG, Davis DHJ, Ansari M, et al. An analytical framework for delirium research in palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge user perspectives. J Pain Symptom Manage. 2014;48(2):159–75.CrossRef
15.
go back to reference Breitbart W, Alici Y. Agitation and delirium at the end of life: “We couldn’t manage him”. JAMA. 2008;300(24):2898–910. E2891.CrossRef Breitbart W, Alici Y. Agitation and delirium at the end of life: “We couldn’t manage him”. JAMA. 2008;300(24):2898–910. E2891.CrossRef
16.
go back to reference Hui D, Reddy A, Palla S, Bruera E. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care. 2011;27(2):141–7.CrossRef Hui D, Reddy A, Palla S, Bruera E. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care. 2011;27(2):141–7.CrossRef
17.
go back to reference Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–14.CrossRef Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–14.CrossRef
18.
go back to reference Cherny NI, Fallon M, Kaasa S, Portenoy KP, Currow DC. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: University Press; 2015. Cherny NI, Fallon M, Kaasa S, Portenoy KP, Currow DC. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: University Press; 2015.
19.
go back to reference Leonard M, Raju B, Conroy M, et al. Reversibility of delirium in terminally ill patients and predictors of mortality. Palliat Med. 2008;22(7):848–54.CrossRef Leonard M, Raju B, Conroy M, et al. Reversibility of delirium in terminally ill patients and predictors of mortality. Palliat Med. 2008;22(7):848–54.CrossRef
20.
go back to reference Braiteh F, El Osta B, Palmer JL, Reddy SK, Bruera E. Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center. J Palliat Med. 2007;10(4):948–55.CrossRef Braiteh F, El Osta B, Palmer JL, Reddy SK, Bruera E. Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center. J Palliat Med. 2007;10(4):948–55.CrossRef
21.
go back to reference Clegg A, Westby M, Young JB. Under-reporting of delirium in the NHS. Age Ageing. 2011;40(2):283–6.CrossRef Clegg A, Westby M, Young JB. Under-reporting of delirium in the NHS. Age Ageing. 2011;40(2):283–6.CrossRef
22.
go back to reference Han JH, Zimmerman EE, Cutler N, et al. Delirium in older emergency department patients: recognition, risk factors, and psychomotor subtypes. Acad Emerg Med. 2009;16(3):193–200.CrossRef Han JH, Zimmerman EE, Cutler N, et al. Delirium in older emergency department patients: recognition, risk factors, and psychomotor subtypes. Acad Emerg Med. 2009;16(3):193–200.CrossRef
23.
go back to reference Leonard MM, Nekolaichuk C, Meagher DJ, et al. Practical assessment of delirium in palliative care. J Pain Symptom Manage. 2014;48(2):176–90.CrossRef Leonard MM, Nekolaichuk C, Meagher DJ, et al. Practical assessment of delirium in palliative care. J Pain Symptom Manage. 2014;48(2):176–90.CrossRef
24.
go back to reference Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. Does this patient have delirium?: value of bedside instruments. JAMA. 2010;304(7):779–86.CrossRef Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. Does this patient have delirium?: value of bedside instruments. JAMA. 2010;304(7):779–86.CrossRef
25.
go back to reference Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999;10(5):393–400.CrossRef Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999;10(5):393–400.CrossRef
26.
go back to reference Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol. 2000;57(12):1727–31.CrossRef Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol. 2000;57(12):1727–31.CrossRef
27.
go back to reference Inouye SK, Bogardus ST Jr., Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.CrossRef Inouye SK, Bogardus ST Jr., Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.CrossRef
28.
go back to reference Morita T, Akechi T, Ikenaga M, et al. Terminal delirium: recommendations from bereaved families’ experiences. J Pain Symptom Manage. 2007;34(6):579–89.CrossRef Morita T, Akechi T, Ikenaga M, et al. Terminal delirium: recommendations from bereaved families’ experiences. J Pain Symptom Manage. 2007;34(6):579–89.CrossRef
29.
go back to reference Hui D. Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication. Curr Opin Support Palliat Care. 2018;12(4):489–94.CrossRef Hui D. Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication. Curr Opin Support Palliat Care. 2018;12(4):489–94.CrossRef
30.
go back to reference Crawford GB, Agar MM, Quinn SJ, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. J Palliat Med. 2013;16(11):1335–41.CrossRef Crawford GB, Agar MM, Quinn SJ, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. J Palliat Med. 2013;16(11):1335–41.CrossRef
31.
go back to reference Yoon HJ, Park KM, Choi WJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Bmc Psychiatry. 2013;13:240.CrossRef Yoon HJ, Park KM, Choi WJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Bmc Psychiatry. 2013;13:240.CrossRef
32.
go back to reference Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2017;177(1):34–42.CrossRef Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2017;177(1):34–42.CrossRef
33.
go back to reference Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in hospitalized adults—a systematic evidence review. J Gen Intern Med. 2009;24(7):848–53.CrossRef Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in hospitalized adults—a systematic evidence review. J Gen Intern Med. 2009;24(7):848–53.CrossRef
34.
go back to reference Morita T, Tsunoda J, Inoue S, Chihara S. Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. Jpn J Clin Oncol. 1999;29(3):156–9.CrossRef Morita T, Tsunoda J, Inoue S, Chihara S. Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. Jpn J Clin Oncol. 1999;29(3):156–9.CrossRef
35.
go back to reference Schildmann E, Schildmann J. Palliative sedation therapy: a systematic literature review and critical appraisal of available guidance on indication and decision making. J Palliat Med. 2014;17(5):601–11.CrossRef Schildmann E, Schildmann J. Palliative sedation therapy: a systematic literature review and critical appraisal of available guidance on indication and decision making. J Palliat Med. 2014;17(5):601–11.CrossRef
36.
go back to reference Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):1161–74.CrossRef Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):1161–74.CrossRef
Metadata
Title
Palliative sedation for delirium management at the end of life
Author
Sophie Roider-Schur
Publication date
01-03-2020
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2020
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00573-5

Other articles of this Issue 1/2020

memo - Magazine of European Medical Oncology 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine